Table 2.
Summary of results for the primary analyses
| Endpoint | Placebo (n = 19; 0–4 h) Mean (SD)/GM (%CV) | Placebo (n = 19; 0–6 h) Mean (SD)/GM (%CV) | Pregabalin 300 mg (n = 19; 0–6 h) | Ibuprofen 600 mg (n = 20; 0–4 h) | PF‐06273340 50 mg (n = 19; 0–4 h) | PF‐06273340 400 mg (n = 19; 0–4 h) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean (SD)/GM (%CV) | LS mean effect vs. placebo (90% CI) | Mean (SD)/GM (%CV) | LS mean effect vs. placebo (90% CI) | Mean (SD)/GM (%CV) | LS mean effect vs. placebo (90% CI) | Mean (SD)/ GM (%CV) | LS mean effect vs. placebo (90% CI) | |||
| Cold pressor PTT | 28.57 (72%) | 28.33 (72%) | 34.07 (72%) | 1.22 (1.11, 1.34) | 28.58 (71%) | 1.05 (0.95, 1.15) | 28.60 (76%) | 0.98 (0.89, 1.08) | 27.69 (76%) | 1.02 (0.93, 1.12) |
| Electrical stair PTT | 23.97 (68%) | 24.20 (68%) | 25.47 (67%) | 1.09 (1.01, 1.19) | 25.96 (67%) | 1.03 (0.95, 1.11) | 24.30 (69%) | 0.97 (0.90, 1.05) | 23.10 (73%) | 0.94 (0.87, 1.02) |
| Pressure pain PTT | 51.99 (67%) | 51.98 (67%) | 58.54 (64%) | 1.07 (0.99, 1.15) | 57.51 (66%) | 1.06 (0.99, 1.14) | 53.02 (67%) | 1.01 (0.93, 1.08) | 55.93 (66%) | 1.05 (0.98, 1.13) |
| Normal heat PDT | 46.73 (2.29) | 46.79 (2.23) | 47.46 (2.09) | 0.35 (−0.11, 0.81) | 46.27 (3.42) | −0.13 (−0.57, 0.31) | 46.68 (2.99) | 0.19 (−0.26, 0.64) | 46.87 (2.59) | 0.16 (−0.29, 0.60) |
| UVB heat PDT | 40.59 (2.49) | 40.59 (2.51) | 41.37 (2.41) | 0.47 (−0.02, 0.95) | 42.12 (2.98) | 1.39 (0.91, 1.87) | 41.21 (2.71) | 0.27 (−0.22, 0.76) | 41.52 (2.60) | 1.13 (0.64, 1.61) |
PTT endpoints were analysed on the log scale, so results are presented as geometric means with %CVs for individual treatment results, and back‐transformed LS mean ratios and 95% CIs for treatment comparisons. CI, confidence interval; CV, coefficient of variation; GM, geometric mean; LS mean, least squares mean; PDT, pain detection threshold; PTT, pain tolerance threshold; SD, standard deviation; UVB, ultraviolet B
Bold text indicates that the effect over placebo met the predefined decision criterion